Conceptus, Inc.

Essure developer reports revised loss of $6.8M

Published in Health Business Week, November 12th, 2004

Conceptus, Inc., (CPTS) developer of the non-incisional permanent birth control procedure Essure, revised financial guidance for the third and fourth quarters of 2004.

Net sales for the third quarter of 2004 are now expected to be approximately $2.8 million, compared with previous guidance of $3.2 million to $3.4 million for the third quarter.

The revision is attributable to lower than expected revenues from the company's copromotion agreement with the Gynecare division of Ethicon, Inc.

The company's net loss guidance for the third quarter is also revised to $6.5 million to $6.8 million, compared with previous net loss guidance of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2004-11-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry